<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01314001</url>
  </required_header>
  <id_info>
    <org_study_id>811722</org_study_id>
    <secondary_id>U01DA020830</secondary_id>
    <nct_id>NCT01314001</nct_id>
  </id_info>
  <brief_title>Pharmacogenetics of Nicotine Addiction Treatment</brief_title>
  <official_title>Pharmacogenetics of Nicotine Addiction Treatment (PNAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research program is to understand how a biomarker called the &quot;nicotine
      metabolite ratio&quot; (also referred to as NMR) may influence a smoker's ability to quit smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smoking is an enormous public health problem with a great need for research to improve
      treatment outcomes. Our prior data indicates that the cytochrome P450 2A6 (CYP2A6) enzyme is
      critical in the metabolic inactivation of nicotine, and also influences smoking behavior and
      response to therapies. With a vision toward translation of our research to practice, we have
      characterized a genetically-informed biomarker of CYP2A6 activity, specifically the nicotine
      metabolite ratio (NMR; 3'hydroxycotinine/cotinine), which reflects both CYP2A6 genetic
      variation and environmental influences on CYP2A6 activity. The NMR is measured non-invasively
      in smokers with established reliability, stability, analytic validity, and efficacy as a
      predictor of the ability to quit smoking and treatment response in multiple retrospective
      trials. Translation of these findings to clinical practice requires validation in a
      prospective clinical trial comparing alternative therapies for smoking cessation. Thus, the
      proposed trial is a prospective, stratified, placebo-controlled, multi-center clinical trial
      of alternative therapies for smoking cessation treatment in approximately 1,200 smokers.
      Randomization to placebo (PLA), transdermal nicotine (TN), or varenicline (VAR) will be
      stratified prospectively based on the nicotine metabolite ratio (NMR). Abstinence from
      smoking at the end of treatment will be the primary outcome. Quit rate at 6-month follow-up
      is a secondary outcome. To facilitate translation to practice, analysis of the
      cost-effectiveness of our proposed approach will also be completed. The proposed research
      provides the next critical step to validate a genetically-informed diagnostic tool, the NMR,
      which clinicians can use in the future to optimize treatment decisions for their patients who
      wish to quit smoking.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day Point Prevalence Quit Rate at End-of-Treatment (EOT)</measure>
    <time_frame>Week 11</time_frame>
    <description>The percentage of ITT subjects who were verified as abstinent. Abstinence was defined as no self-reported smoking (not even a puff) for at least 7 days before the telephone assessment, with in-person verification for those self-reporting abstinence. In-person verification consisted of breath carbon monoxide analysis, with a reading of 8 parts-per-million or less confirming abstinence. Subjects who were lost to follow-up were considered smokers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>7-day Point Prevalence Quit Rate at 6-month Follow up Survey</measure>
    <time_frame>Week 24</time_frame>
    <description>The percentage of ITT subjects who were verified as abstinent at the 6-month follow up survey. Abstinence was defined as no self-reported smoking (not even a puff) for at least 7 days before the telephone assessment, with in-person verification for those self-reporting abstinence. In-person verification consisted of breath carbon monoxide analysis, with a reading of 8 parts-per-million or less confirming abstinence. Subjects who were lost to follow-up were considered smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Side-Effect Severity Index at Pre-Quit</measure>
    <time_frame>Pre-Quit (Week -1/Baseline)</time_frame>
    <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Side-Effect Severity Index at Target Quit Date</measure>
    <time_frame>Target Quit Date (Week 0)</time_frame>
    <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Side-Effect Severity Index at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Side-Effect Severity Index at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1246</enrollment>
  <condition>Nicotine Addiction</condition>
  <arm_group>
    <arm_group_label>Placebo (Slow Metabolizers)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks &amp; wear a placebo patch daily for eleven weeks.
The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.
The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.
All subjects in this arm will receive smoking cessation counseling during their sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline (Slow Metabolizers)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks &amp; wear a placebo patch daily for eleven weeks.
When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.
The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.
All subjects in this arm will receive smoking cessation counseling during their sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal Nicotine (Slow Metabolizers)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks &amp; will wear an active transdermal nicotine patch daily for eleven weeks.
The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.
When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.
All subjects in this arm will receive smoking cessation counseling during their sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Normal Metabolizers)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks &amp; wear a placebo patch daily for eleven weeks.
The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.
The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.
All subjects in this arm will receive smoking cessation counseling during their sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline (Normal Metabolizers)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks &amp; wear a placebo patch daily for eleven weeks.
When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.
The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.
All subjects in this arm will receive smoking cessation counseling during their sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal Nicotine (Normal Metabolizers)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks &amp; will wear an active transdermal nicotine patch daily for eleven weeks.
The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.
When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.
All subjects in this arm will receive smoking cessation counseling during their sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally</description>
    <arm_group_label>Varenicline (Slow Metabolizers)</arm_group_label>
    <arm_group_label>Varenicline (Normal Metabolizers)</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch</description>
    <arm_group_label>Placebo (Slow Metabolizers)</arm_group_label>
    <arm_group_label>Placebo (Normal Metabolizers)</arm_group_label>
    <other_name>Placebo pills</other_name>
    <other_name>Placebo patches</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal Nicotine</intervention_name>
    <description>Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch</description>
    <arm_group_label>Transdermal Nicotine (Slow Metabolizers)</arm_group_label>
    <arm_group_label>Transdermal Nicotine (Normal Metabolizers)</arm_group_label>
    <other_name>Nicoderm CQ</other_name>
    <other_name>Nicotine Patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligible participants will be males and females

          1. Between the ages of 18-65.

          2. Smoke at least 10 cigarettes/day for the past 6 months.

          3. Provide a baseline Carbon Monoxide (CO) reading greater than 10ppm at the Intake
             Session.

          4. Are seeking smoking cessation treatment.

          5. Plan to live in the area for the next 12 months.

          6. Fluent English speaker.

          7. Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the combined consent and Health Insurance
             Portability and Accountability Act (HIPAA) form. All subjects must consent to use a
             medically accepted method of birth control (e.g., condoms and spermicide, oral
             contraceptive, Depo-Provera injection, contraceptive patch, tubal ligation) or abstain
             from sexual intercourse during the time they are taking study medication (pills and
             patches) and for at least one month after the medication period ends. All female
             subjects of child-bearing potential should not be pregnant for the duration of the
             study.

        Exclusion Criteria:

        Smoking Behavior

          1. Regular (daily) use of chewing tobacco, snuff or snus.

          2. Current enrollment or plans to enroll in another smoking cessation or research program
             in the next 12 months.

          3. Plan to use other nicotine substitutes or smoking cessation treatments in the next 12
             months.

          4. Provide a baseline CO reading less than or equal to 10ppm at the Intake Session.

        Alcohol/Drug Exclusion Criteria

          1. History (within the last year) or currently receiving treatment for substance abuse
             (e.g., alcohol, opioids, cocaine, marijuana, or stimulants), excluding nicotine.

          2. Current use of cocaine and/or methamphetamines (urine drug screen at the Intake
             Session).

          3. Current alcohol consumption that exceeds greater than 25 standard drinks/week.

          4. Current alcohol abuse or dependence.

          5. Current non-alcoholic psychoactive substance abuse or dependence.

        Medical Exclusion Criteria

          1. Women who are pregnant, planning a pregnancy, or lactating.

          2. History of epilepsy or a seizure disorder.

          3. Current medical problems for which transdermal nicotine is contraindicated including:

               -  Allergy to latex.

               -  History of kidney and/or liver disease, including transplant (self-report).

               -  Uncontrolled hypertension (determined as a Systolic Blood pressure (SBP) reading
                  greater than 160 and/or a Diastolic Blood Pressure (DBP) greater than 100).

          4. Serious or unstable disease within the past 6 months.

          5. History (last 6 months) of abnormal heart rhythms, tachycardia and cardiovascular
             disease (stroke, angina, heart attack) may result in ineligibility. These conditions
             will be evaluated on a case by case basis by the Study Physician.

          6. Inability to provide a blood sample to be used to assess nicotine metabolite ratio.

        Psychiatric Exclusion Criteria (as determined by self report &amp; MINI)

          1. Current diagnosis of major depression. Persons with a history of major depression, if
             stable for 6 months or longer, are eligible, provided they are not excluded based on
             medications (below).

          2. Any suicide risk score on MINI or self-reported suicide attempt on telephone screen.

          3. Current or past hypomanic/manic episode.

          4. History or current diagnosis of Post Traumatic Stress Disorder (PTSD).

          5. History or current diagnosis of psychotic disorder, bipolar disorder, schizophrenia.

        Medication Exclusion Criteria

          1. Current use or recent discontinuation (within the last 14-days) of:

               -  Smoking cessation medication (e.g. Zyban, Wellbutrin, Wellbutrin SR, Chantix);
                  NOTE: Once participants are found eligible for the study, they are instructed to
                  use the smoking cessation medication provided to them by the study staff. If a
                  subject reports an isolated (non-daily) instance of using a non-study smoking
                  cessation medication, the study physician and PI will evaluate the situation and
                  determine if it is safe for the subject to continue participation.

               -  Anti-psychotic medications.

               -  Certain medications used to treat depression, including Wellbutrin, Monoamine
                  Oxidase Inhibitors (MAOIs), and tricyclic antidepressants.

               -  Prescription stimulants (e.g. Provigil, Ritalin, Adderall).

          2. Current use of:

               -  Nicotine replacement therapy (NRT); NOTE: Once participants are found eligible
                  for the study, they are told they should only use the NRT provided to them by the
                  study staff. If a subject reports an isolated (non-daily) instance of NRT use
                  during the study, they may be permitted to continue.

               -  Tagamet (cimetidine).

               -  Heart medications such as digoxin, quinidine, nitroglycerin; use of these
                  medications may result in ineligibility and will therefore be evaluated on a
                  case-by-case basis by the Study Physician.

               -  Anti-coagulants (e.g., Coumadin, Warfarin).

          3. Daily use of:

               -  Opiate-containing medications for chronic pain; if a participant reports taking
                  an opiate-containing medication every day for the 14 days prior to the telephone
                  screen and/or Intake Session, the participant will be ineligible.

               -  Rescue Inhalers (e.g. albuterol, proventil, ventolin, or maxair)

        General Exclusion

          1. Any medical condition, illness, disorder or concomitant medication that could
             compromise participant safety or treatment, as determined by the Principal
             Investigator and/or Study Physician.

          2. Inability to provide informed consent or complete any of the study tasks as determined
             by the Principal Investigator and/or Study Physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caryn Lerman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rachel F Tyndale, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University at Buffalo - State University of New York</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center, University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health, University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T1RH</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <results_first_submitted>January 4, 2016</results_first_submitted>
  <results_first_submitted_qc>February 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2016</results_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tobacco, Smoking, Varenicline, Nicotine Patch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at four academic medical centers. From 11/16/2010 to 9/16/2013, participants were recruited through advertisements for a free smoking cessation program.</recruitment_details>
      <pre_assignment_details>Subjects were randomly assigned to one of three treatment groups in a 1:1:1 ratio: &quot;Placebo&quot;; &quot;Nicotine Patch&quot;; or &quot;Varenicline&quot;. Randomization was stratified by nicotine metabolite ratio - slow metabolizers of nicotine vs. normal metabolizers - and study site and blocked in blocks of 12 to maintain balance. Slow metabolizers were over-sampled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Slow Metabolizers)</title>
          <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Normal Metabolizers)</title>
          <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="P3">
          <title>Nicotine Patch (Slow Metabolizers)</title>
          <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="P4">
          <title>Nicotine Patch (Normal Metabolizers)</title>
          <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="P5">
          <title>Varenicline (Slow Metabolizers)</title>
          <description>Slow metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="P6">
          <title>Varenicline (Normal Metabolizers)</title>
          <description>Normal metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
                <participants group_id="P2" count="193"/>
                <participants group_id="P3" count="227"/>
                <participants group_id="P4" count="191"/>
                <participants group_id="P5" count="220"/>
                <participants group_id="P6" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>End-of-Treatment Visit</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="141"/>
                <participants group_id="P3" count="179"/>
                <participants group_id="P4" count="146"/>
                <participants group_id="P5" count="174"/>
                <participants group_id="P6" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6-Month Follow Up Survey</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="165"/>
                <participants group_id="P4" count="135"/>
                <participants group_id="P5" count="157"/>
                <participants group_id="P6" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="122"/>
                <participants group_id="P5" count="148"/>
                <participants group_id="P6" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="69"/>
                <participants group_id="P5" count="72"/>
                <participants group_id="P6" count="71"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The number of subjects who began treatment period in the project (intention-to-treat).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Slow Metabolizers)</title>
          <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Normal Metabolizers)</title>
          <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="B3">
          <title>Nicotine Patch (Slow Metabolizers)</title>
          <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="B4">
          <title>Nicotine Patch (Normal Metabolizers)</title>
          <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="B5">
          <title>Varenicline (Slow Metabolizers)</title>
          <description>Slow metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="B6">
          <title>Varenicline (Normal Metabolizers)</title>
          <description>Normal metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="215"/>
            <count group_id="B2" value="193"/>
            <count group_id="B3" value="227"/>
            <count group_id="B4" value="191"/>
            <count group_id="B5" value="220"/>
            <count group_id="B6" value="200"/>
            <count group_id="B7" value="1246"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="11"/>
                    <measurement group_id="B2" value="47" spread="11"/>
                    <measurement group_id="B3" value="46" spread="11"/>
                    <measurement group_id="B4" value="46" spread="11"/>
                    <measurement group_id="B5" value="44" spread="12"/>
                    <measurement group_id="B6" value="46" spread="12"/>
                    <measurement group_id="B7" value="45" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="94"/>
                    <measurement group_id="B5" value="88"/>
                    <measurement group_id="B6" value="99"/>
                    <measurement group_id="B7" value="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="139"/>
                    <measurement group_id="B4" value="97"/>
                    <measurement group_id="B5" value="132"/>
                    <measurement group_id="B6" value="101"/>
                    <measurement group_id="B7" value="703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="99"/>
                    <measurement group_id="B6" value="133"/>
                    <measurement group_id="B7" value="693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="107"/>
                    <measurement group_id="B6" value="53"/>
                    <measurement group_id="B7" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="149"/>
                    <measurement group_id="B5" value="172"/>
                    <measurement group_id="B6" value="156"/>
                    <measurement group_id="B7" value="970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education level</title>
          <description>Question on Demographics measure (self-report) completed at the Intake session (&quot;What is the highest level of education you completed?&quot;).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>High school education or lower</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="74"/>
                    <measurement group_id="B6" value="61"/>
                    <measurement group_id="B7" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-high school education</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="142"/>
                    <measurement group_id="B5" value="146"/>
                    <measurement group_id="B6" value="139"/>
                    <measurement group_id="B7" value="859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Annual Income (US dollars)</title>
          <description>Question on Demographics measure (self-report) completed at the Intake session (&quot;What was your household income before taxes last year?&quot;).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greater than or equal to US$50,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="74"/>
                    <measurement group_id="B6" value="71"/>
                    <measurement group_id="B7" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than US$50,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="116"/>
                    <measurement group_id="B5" value="146"/>
                    <measurement group_id="B6" value="129"/>
                    <measurement group_id="B7" value="800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment Status</title>
          <description>Question on Demographics measure (self-report) completed at the Intake session (&quot;Are you currently employed full-time or part-time for salary or wages?&quot;).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="88"/>
                    <measurement group_id="B6" value="75"/>
                    <measurement group_id="B7" value="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="132"/>
                    <measurement group_id="B6" value="125"/>
                    <measurement group_id="B7" value="780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FTND Score</title>
          <description>The Fagerstrom Test for Nicotine Dependence (FTND) is a six-item self-report scale that measures the level of nicotine dependence. Summary scores are calculated, ranging from 0 to 10, with higher scores indicating a greater difficulty quitting smoking.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" spread="1.92"/>
                    <measurement group_id="B2" value="5.4" spread="2.00"/>
                    <measurement group_id="B3" value="5.2" spread="2.00"/>
                    <measurement group_id="B4" value="5.3" spread="1.89"/>
                    <measurement group_id="B5" value="5.1" spread="2.00"/>
                    <measurement group_id="B6" value="2.1" spread="2.02"/>
                    <measurement group_id="B7" value="5.2" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes per day</title>
          <description>Self-report measure of the number of cigarettes smoked in a typical day.</description>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.6" spread="7.0"/>
                    <measurement group_id="B2" value="19.6" spread="8.7"/>
                    <measurement group_id="B3" value="17.6" spread="7.0"/>
                    <measurement group_id="B4" value="18.5" spread="7.0"/>
                    <measurement group_id="B5" value="16.7" spread="5.4"/>
                    <measurement group_id="B6" value="18.4" spread="6.3"/>
                    <measurement group_id="B7" value="18.0" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7-day Point Prevalence Quit Rate at End-of-Treatment (EOT)</title>
        <description>The percentage of ITT subjects who were verified as abstinent. Abstinence was defined as no self-reported smoking (not even a puff) for at least 7 days before the telephone assessment, with in-person verification for those self-reporting abstinence. In-person verification consisted of breath carbon monoxide analysis, with a reading of 8 parts-per-million or less confirming abstinence. Subjects who were lost to follow-up were considered smokers.</description>
        <time_frame>Week 11</time_frame>
        <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Patch (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O5">
            <title>Varenicline (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O6">
            <title>Varenicline (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence Quit Rate at End-of-Treatment (EOT)</title>
          <description>The percentage of ITT subjects who were verified as abstinent. Abstinence was defined as no self-reported smoking (not even a puff) for at least 7 days before the telephone assessment, with in-person verification for those self-reporting abstinence. In-person verification consisted of breath carbon monoxide analysis, with a reading of 8 parts-per-million or less confirming abstinence. Subjects who were lost to follow-up were considered smokers.</description>
          <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
          <units>percentage of ITT subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="191"/>
                <count group_id="O5" value="220"/>
                <count group_id="O6" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="18.6"/>
                    <measurement group_id="O3" value="27.7"/>
                    <measurement group_id="O4" value="22.5"/>
                    <measurement group_id="O5" value="30.4"/>
                    <measurement group_id="O6" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7-day Point Prevalence Quit Rate at 6-month Follow up Survey</title>
        <description>The percentage of ITT subjects who were verified as abstinent at the 6-month follow up survey. Abstinence was defined as no self-reported smoking (not even a puff) for at least 7 days before the telephone assessment, with in-person verification for those self-reporting abstinence. In-person verification consisted of breath carbon monoxide analysis, with a reading of 8 parts-per-million or less confirming abstinence. Subjects who were lost to follow-up were considered smokers.</description>
        <time_frame>Week 24</time_frame>
        <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Patch (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O5">
            <title>Varenicline (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O6">
            <title>Varenicline (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence Quit Rate at 6-month Follow up Survey</title>
          <description>The percentage of ITT subjects who were verified as abstinent at the 6-month follow up survey. Abstinence was defined as no self-reported smoking (not even a puff) for at least 7 days before the telephone assessment, with in-person verification for those self-reporting abstinence. In-person verification consisted of breath carbon monoxide analysis, with a reading of 8 parts-per-million or less confirming abstinence. Subjects who were lost to follow-up were considered smokers.</description>
          <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
          <units>percentage of ITT subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="191"/>
                <count group_id="O5" value="220"/>
                <count group_id="O6" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="12.9"/>
                    <measurement group_id="O3" value="21.6"/>
                    <measurement group_id="O4" value="13.6"/>
                    <measurement group_id="O5" value="19.1"/>
                    <measurement group_id="O6" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Side-Effect Severity Index at Pre-Quit</title>
        <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
        <time_frame>Pre-Quit (Week -1/Baseline)</time_frame>
        <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Patch (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O5">
            <title>Varenicline (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O6">
            <title>Varenicline (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Side-Effect Severity Index at Pre-Quit</title>
          <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
          <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="191"/>
                <count group_id="O5" value="220"/>
                <count group_id="O6" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" spread="4.84"/>
                    <measurement group_id="O2" value="3.40" spread="4.34"/>
                    <measurement group_id="O3" value="3.26" spread="3.97"/>
                    <measurement group_id="O4" value="3.97" spread="4.74"/>
                    <measurement group_id="O5" value="3.05" spread="3.93"/>
                    <measurement group_id="O6" value="3.57" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Side-Effect Severity Index at Target Quit Date</title>
        <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
        <time_frame>Target Quit Date (Week 0)</time_frame>
        <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Patch (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O5">
            <title>Varenicline (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O6">
            <title>Varenicline (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Side-Effect Severity Index at Target Quit Date</title>
          <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
          <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="191"/>
                <count group_id="O5" value="220"/>
                <count group_id="O6" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" spread="4.37"/>
                    <measurement group_id="O2" value="4.27" spread="4.57"/>
                    <measurement group_id="O3" value="3.98" spread="3.59"/>
                    <measurement group_id="O4" value="4.28" spread="4.96"/>
                    <measurement group_id="O5" value="4.68" spread="4.66"/>
                    <measurement group_id="O6" value="4.06" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Side-Effect Severity Index at Week 1</title>
        <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
        <time_frame>Week 1</time_frame>
        <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Patch (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O5">
            <title>Varenicline (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O6">
            <title>Varenicline (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Side-Effect Severity Index at Week 1</title>
          <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
          <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="191"/>
                <count group_id="O5" value="220"/>
                <count group_id="O6" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" spread="5.08"/>
                    <measurement group_id="O2" value="5.46" spread="5.00"/>
                    <measurement group_id="O3" value="5.44" spread="5.03"/>
                    <measurement group_id="O4" value="5.58" spread="5.48"/>
                    <measurement group_id="O5" value="6.04" spread="5.23"/>
                    <measurement group_id="O6" value="5.26" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Side-Effect Severity Index at Week 4</title>
        <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
        <time_frame>Week 4</time_frame>
        <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Patch (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O5">
            <title>Varenicline (Slow Metabolizers)</title>
            <description>Slow metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
          <group group_id="O6">
            <title>Varenicline (Normal Metabolizers)</title>
            <description>Normal metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Side-Effect Severity Index at Week 4</title>
          <description>The mean side-effect severity score by treatment group (placebo vs. nicotine patch vs. varenicline) and by NMR group (slow metabolizers vs. normal metabolizers).
Side-effect severity was calculated using a Side Effects Checklists (SEC). 29 common side-effects associated with transdermal nicotine or varenicline treatment were rated by participants on a 0 (none) to 3 (severe) scale. For each participant at this timepoint, these scores were summed to calculate a total score, with a range of 0 to 87; a higher score indicated a higher severity of side-effects.</description>
          <population>Intent-to-treat population (all subjects who received at least one dose of intervention).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="191"/>
                <count group_id="O5" value="220"/>
                <count group_id="O6" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="5.70"/>
                    <measurement group_id="O2" value="4.93" spread="5.68"/>
                    <measurement group_id="O3" value="4.24" spread="4.40"/>
                    <measurement group_id="O4" value="4.52" spread="5.46"/>
                    <measurement group_id="O5" value="4.97" spread="4.88"/>
                    <measurement group_id="O6" value="4.39" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected throughout the entire span of each subject's participation, which is approximately 1 year, 1 month (from initial phone screening to the 12-month follow up survey).</time_frame>
      <desc>Systematic Assessment: subjects completed a side effect checklist (SEC) during each study session over the course of the treatment period (target quit date through end-of-treatment). The SEC listed anticipated side effects that could be caused by the study medication. Subjects could also spontaneously report AEs at any time.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Slow Metabolizers)</title>
          <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Normal Metabolizers)</title>
          <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing placebo patches daily for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="E3">
          <title>Nicotine Patch (Slow Metabolizers)</title>
          <description>Slow metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="E4">
          <title>Nicotine Patch (Normal Metabolizers)</title>
          <description>Normal metabolizers
Taking placebo pills daily for 12 weeks
Wearing active nicotine patches for 11 weeks (6 weeks of 21mg, 2 weeks of 14mg, 3 weeks of 7mg)
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="E5">
          <title>Varenicline (Slow Metabolizers)</title>
          <description>Slow metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
        <group group_id="E6">
          <title>Varenicline (Normal Metabolizers)</title>
          <description>Normal metabolizers
Taking active varenicline pills daily for 12 weeks (3 days of 0.5mg daily, 4 days of 0.5mg twice daily, and 77 days of 1mg twice daily)
Wearing placebo patches for 11 weeks
Received smoking cessation counseling during their sessions</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Episode of atrial fibrillation that required hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Heart Attack</sub_title>
                <description>Episodes of heart attack or heart attack-like symptoms</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes diagnosis</sub_title>
                <description>Diagnosis made during hospitalization following heart attack-like symptoms</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Severe nausea/vomiting/abdominal pain</sub_title>
                <description>Symptoms severe enough to require hospitalization.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Tongue Swelling</sub_title>
                <description>Hospitalization due to swelling of the tongue</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gall bladder issues</sub_title>
                <description>Hospitalized due to surgery or issues of the gall bladder</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Hospitalization due to pneumonia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Broken bones</sub_title>
                <description>Broken bones due to accidents</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Knee injuries</sub_title>
                <description>Knee injuries; may require surgery</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer; colon</sub_title>
                <description>Diagnosis of colon cancer</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Cancer; lung</sub_title>
                <description>Diagnosis of lung cancer</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Cancer; oral</sub_title>
                <description>Diagnosis of oral cancer</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Cancer; throat</sub_title>
                <description>Diagnosis of throat cancer</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Moderate cervical dysplasia</sub_title>
                <description>Unknown whether benign or malignant</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures; cause unknown</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Panic Attacks</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Sleep problems</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Suicidal thoughts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney stone procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD diagnosis</sub_title>
                <description>Hospitalization; COPD diagnosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Severe asthma attack</sub_title>
                <description>Required hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abscess drainage; surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Skin/bone biopsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Brain aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="206" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="169" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="210" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="185" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Heart Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Irregular Heartbeat</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="71" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="94" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="81" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Gas</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="91" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="111" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="98" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="54" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="97" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="94" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="111" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="62" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="88" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="79" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="88" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="60" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Body Weakness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Feel Weakness</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Dreams</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="97" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="89" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="96" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="84" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="71" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="73" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="56" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="49" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Disturbed Attention</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Hostility</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="83" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="60" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="130" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="119" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="128" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="114" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Sleep Problems</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="118" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="109" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Suicidal Thoughts</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Redness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Skin Swelling/Rash</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="220"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation is that few Hispanics or Asians were included.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul M. Sanborn, M.S.</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-746-7150</phone>
      <email>sanborn@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

